← Back to Search

Minds and Mentors Program for Opioid Use Disorder (MiMP Trial)

N/A
Recruiting
Research Sponsored by University of Alabama, Tuscaloosa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 19 and older
Currently receiving MOUD (e.g. methadone, naloxone, naltrexone, and buprenorphine) from an established provider
Must not have
Significant cognitive impairment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests the Minds and Mentors Program, a group therapy that uses mindfulness and peer support, in people with opioid use disorder who are on medication. The goal is to see if it helps them stick to their medication, reduces relapse rates, and lowers stress and cravings. Mindfulness-based relapse prevention (MBRP) includes the teaching and practice of mindfulness meditation to help patients change their relationship to drug cravings and other negative emotional states.

Who is the study for?
This trial is for adults over 19 with opioid use disorder who are currently on medication-assisted treatment (like methadone or buprenorphine). They must be stable on their medication, able to attend 12 therapy sessions and follow-ups for 9 months, have internet access, and not be in immediate need of intensive care like detox. Pregnant women, those with unstable medical conditions or active psychosis, suicidal thoughts, or significant cognitive impairment cannot join.
What is being tested?
The study tests the Minds and Mentors Program against a Twelve Step Facilitation program for people using medications to treat opioid addiction. Participants will randomly receive one of these treatments in groups of five. The goal is to see if the program helps stick to treatment better, reduces relapse and cravings, lowers anxiety/stress/depression levels, and affects cortisol related to drug cues.
What are the potential side effects?
Since this trial involves group therapy programs rather than medications beyond participants' current treatments for opioid use disorder (MOUD), there aren't new side effects from drugs being tested here. However, discussing sensitive topics during therapy could potentially cause emotional discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 19 years old or older.
Select...
I am currently on medication for opioid use disorder.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have significant difficulty with my memory or thinking.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adherence Rate
Secondary study objectives
Anxiety
Cravings
Depression
+3 more
Other study objectives
Cortisol Reactivity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Mindfulness based relapse prevention and peer mentoringExperimental Treatment1 Intervention
Treatment will utilize a group format. The twelve-week mindfulness based relapsed prevention group therapy intervention is co-led by a licensed counselor and a peer mentor for eight weeks, followed by group sessions led by peer mentors for an additional four weeks.
Group II: 12 Step Treatment ProgramActive Control1 Intervention
Participants in the attentional control group will attend 12 weeks of a enhanced 12 step treatment program.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Opioid Use Disorder (OUD) include Medication for Opioid Use Disorder (MOUD) and behavioral interventions. MOUD, such as methadone, buprenorphine, and naltrexone, works by binding to opioid receptors in the brain to reduce cravings and withdrawal symptoms, stabilizing brain chemistry. Behavioral interventions like cognitive-behavioral therapy (CBT) and contingency management aim to change the patient's behavior and thought patterns related to drug use. These treatments help improve adherence to MOUD, reduce relapse rates, and decrease psychological stress and cortisol levels. Combining these approaches addresses both the physiological and psychological aspects of OUD, enhancing the effectiveness of long-term recovery efforts.
Efficacy and mechanisms of a single-session behavioral medicine class among patients with chronic pain taking prescription opioids: study protocol for a randomized controlled trial.

Find a Location

Who is running the clinical trial?

University of Alabama, TuscaloosaLead Sponsor
46 Previous Clinical Trials
17,338 Total Patients Enrolled
University of Alabama at BirminghamOTHER
1,635 Previous Clinical Trials
2,304,919 Total Patients Enrolled
Tuscaloosa Veterans Affairs Medical CenterFED
5 Previous Clinical Trials
453 Total Patients Enrolled

Media Library

Minds and Mentors Clinical Trial Eligibility Overview. Trial Name: NCT05363371 — N/A
Opioid Use Disorder Research Study Groups: Mindfulness based relapse prevention and peer mentoring, 12 Step Treatment Program
Opioid Use Disorder Clinical Trial 2023: Minds and Mentors Highlights & Side Effects. Trial Name: NCT05363371 — N/A
Minds and Mentors 2023 Treatment Timeline for Medical Study. Trial Name: NCT05363371 — N/A
Opioid Use Disorder Patient Testimony for trial: Trial Name: NCT05363371 — N/A
~64 spots leftby Oct 2025